Endocrine Abstracts

Since its first description as a phosphaturic agent in the early 2000s, the Fibroblast Growth Factor 23 (FGF23) has rapidly become the third key player of phosphate/calcium metabolism with the two ‘old’ PTH and vitamin D.FGF23 is a protein synthesized by osteocytes that has three main effects: hypophosphatemia (through an inhibition of phosphate reabsorption in the proximal tubule), decreased PTH levels and decreased 1–25 OH2 le...

Fibroblast growth factor-23 (FGF23) FGF23 is a bone-derived hormone which down-regulates renal proximal tubular phosphate reuptake and 1α-hydroxylase expression, the key enzyme for production of the vitamin D hormone, 1α, 25-dihydroxyvitamin D3 (1.25(OH)2D). The molecular mechanism of the phosphaturic action of FGF23 has recently been elucidated. FGF23 directly downregulates membrane expression of the sodium-phosphate cotransporter NaPi-2a in pr...

The discovery that mutations in fibroblast growth factor 23 (FGF23) cause autosomal dominant hypophosphatemic rickets transformed our understanding of phosphate homeostasis in health and disease (White et al. Nat Genet 2000). Since then, the critical role of FGF23 in mineral metabolism in chronic kidney disease has been established (Larsson et al. Kidney Int 2003; Gutierrez et al. J Am Soc Nephrol 2005). Elevated FGF23 has ...